PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-166.83%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-35.81%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-35.81%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
1.74%
Interest expense change of 1.74% while CRVO maintains costs. Bruce Berkowitz would investigate control.
-142558.33%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-488.78%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
36.41%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
2042.35%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.49%
Tax expense change of 4.49% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
439.57%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
440.81%
EPS growth while CRVO declines. John Neff would investigate advantages.
440.81%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.